

Teradyne Reports Fourth Quarter and Fiscal Year 2021 Results

January 26, 2022

- Revenue of \$885 million in Q4'21, growth of 17% from Q4'20
- Full year 2021 revenue grew 19%, GAAP EPS grew 30%, Non-GAAP EPS grew 29% from 2020
- Test Revenue grew 16% in Q4'21 from Q4'20, 17% in FY'21
- Universal Robots Revenue grew 22% in Q4'21 from Q4'20, 41% in FY'21
- MiR Revenue grew 46% in Q4'21 from Q4'20, 42% in FY'21
- Quarterly dividend increased 10% to \$0.11
- Expect to repurchase a minimum of \$750 million in shares in 2022

	Q4'21	Q4'20	Q3'21	FY 2021	FY 2020
Revenue (mil)	\$885	\$759	\$951	\$3,703	\$3,121
GAAP EPS	\$1.29	\$1.05	\$1.41	\$5.56	\$4.28
Non-GAAP EPS	\$1.37	\$1.10	\$1.59	\$5.98	\$4.62

NORTH READING, Mass., Jan. 26, 2022 (GLOBE NEWSWIRE) -- <u>Teradyne. Inc.</u> (NASDAQ: TER) reported revenue of \$885 million for the fourth quarter of 2021 of which \$592 million was in Semiconductor Test, \$127 million in System Test, \$52 million in Wireless Test and \$113 million in Industrial Automation (IA). GAAP net income for the fourth quarter was \$230.3 million or \$1.29 per diluted share. On a non-GAAP basis, Teradyne's net income in the fourth quarter was \$238.4 million, or \$1.37 per diluted share, which excluded acquired intangible asset amortization, restructuring and other charges, losses on convertible debt conversions, and included the related tax impact on non-GAAP adjustments.

"Both our test and industrial automation businesses delivered another quarter of double-digit revenue growth compared with the year ago period," said CEO and President Mark Jagiela. "2021 was a remarkable year for Teradyne as we increased annual sales by 19% and grew non-GAAP earnings per share by 29%, capping a five year stretch where revenue and earnings grew at an annual compounded rate of 16% and 32% respectively. Significantly, our Universal Robots and MiR businesses are seeing high demand which drove greater than 40% growth in 2021.

"We enter 2022 with strong long-term test and automation demand trends in place and we've increased the mid-point of the revenue and non-GAAP earnings per share estimates in our 2024 earnings model to \$4.9 billion and \$8.00 respectively. However, in 2022, we expect a slower technology transition in one of our major end markets to result in lower System-on-a Chip test demand for Teradyne before accelerating again during the ramp of 3nm production in 2023. In Industrial Automation, we expect high growth to continue in 2022 on the strength of favorable global economic trends and the powerful value our automation products provide to customers."

Teradyne's Board of Directors declared a 10% increase in the quarterly cash dividend to \$0.11 per share, payable on March 18, 2022 to shareholders of record as of the close of business on February 18, 2022. The company also expects to repurchase a minimum of \$750 million of its common stock in 2022.

Guidance for the first quarter of 2022 is revenue of \$700 million to \$770 million, with GAAP net income of \$0.71 to \$0.93 per diluted share and non-GAAP net income of \$0.76 to \$0.98 per diluted share. Non-GAAP guidance excludes acquired intangible asset amortization, non-cash convertible debt interest and includes the related tax impact on non-GAAP adjustments.

Webcast

A conference call to discuss the fourth quarter results, along with management's business outlook, will follow at 8:30 a.m. ET, Thursday, January 27. Interested investors should access the webcast at www.teradyne.com and click on "Investors" at least five minutes before the call begins. Presentation materials will be available starting at 8:30 a.m. ET. A replay will be available on the Teradyne website at www.teradyne.com/investors.

Non-GAAP Results

In addition to disclosing results that are determined in accordance with GAAP, Teradyne also discloses non-GAAP results of operations that exclude certain income items and charges. These results are provided as a complement to results provided in accordance with GAAP. Non-GAAP income from operations and non-GAAP net income exclude losses on convertible debt conversions, acquired intangible assets amortization, non-cash convertible debt interest, pension actuarial gains and losses, discrete income tax adjustments, fair value inventory step-up, and restructuring and other, and includes the related tax impact on non-GAAP adjustments. GAAP requires that these items be included in determining income from operations and net income. Non-GAAP income from operations, non-GAAP net income, non-GAAP income from operations as a percentage of revenue, and non-GAAP net income per share are non-GAAP performance measures presented to provide meaningful supplemental information regarding Teradyne's baseline performance before gains, losses or other charges that may not be indicative of Teradyne's current core business or future outlook. These non-GAAP performance measures are used to make operational decisions, to determine employee compensation, to forecast future operational results, and for comparison with Teradyne's business plan, historical operating results and the operating results of Teradyne's competitors. Non-GAAP gross margin excludes fair value inventory step-up. GAAP requires that this item be included in

determining gross margin. Non-GAAP gross margin dollar amount and percentage are non-GAAP performance measures that management believes provide useful supplemental information for management and the investor. Management uses non-GAAP gross margin as a performance measure for Teradyne's current core business and future outlook and for comparison with Teradyne's business plan, historical gross margin results and the gross margin results of Teradyne's competitors. Non-GAAP diluted shares include the impact of Teradyne's call option on its shares. Management believes each of these non-GAAP performance measures provides useful supplemental information for investors, allowing greater transparency to the information used by management in its operational decision making and in the review of Teradyne's financial and operational performance, as well as facilitating meaningful comparisons of Teradyne's results in the current period compared with those in prior and future periods. A reconciliation of each available GAAP to non-GAAP financial measure discussed in this press release is contained in the attached exhibits and on the Teradyne website at www.teradyne.com by clicking on "Investor Relations" and then selecting "Financials" and the "GAAP to Non-GAAP Reconciliation" link. The non-GAAP performance measures discussed in this press release may not be comparable to similarly titled measures used by other companies. The presentation of non-GAAP measures is not meant to be considered in isolation, as a substitute for, or superior to, financial measures or information provided in accordance with GAAP.

About Teradyne

Teradyne (NASDAQ:TER) brings high-quality innovations such as smart devices, life-saving medical equipment and data storage systems to market, faster. Its advanced test solutions for semiconductors, electronic systems, wireless devices and more ensure that products perform as they were designed. Its Industrial Automation offerings include collaborative and mobile robots that help manufacturers of all sizes improve productivity and lower costs. In 2021, Teradyne had revenue of \$3.7 billion and today employs over 5,800 people worldwide. For more information, visit teradyne.com. Teradyne[®] is a registered trademark of Teradyne, Inc. in the U.S. and other countries.

Safe Harbor Statement

This release contains forward-looking statements regarding Teradyne's future business prospects, the impact of the COVID-19 pandemic, results of operations, market conditions, earnings per share, supply chain impact on the business, customer sales expectations, the payment of a quarterly dividend, the repurchase of Teradyne common stock pursuant to a share repurchase program, and the impact of U.S. and Chinese export and tariff laws. Such statements are based on the current assumptions and expectations of Teradyne's management and are neither promises nor guarantees of future performance, events, customer sales, supply chain improvement, earnings per share, use of cash, payment of dividends, repurchases of common stock, payment of the senior convertible notes, the impact of the COVID-19 pandemic, or the impact of U.S. and Chinese export and tariff laws. There can be no assurance that management's estimates of Teradyne's future results or other forward-looking statements will be achieved. Specifically, Teradyne's 2024 earnings model is aspirational and includes many assumptions. There can be no assurance that these assumptions will be accurate or that model results will be achieved. As set forth below, there are many factors that could cause our 2024 earnings model and actual results to differ materially from those presently expected. Additionally, the current dividend and share repurchase programs may be modified, suspended or discontinued at any time.

On May 16, 2019, Huawei and 68 of its affiliates, including HiSilicon, were added to the U.S. Department of Commerce Entity List under U.S. Export Administration Regulations (the "EAR"). This action by the U.S. Department of Commerce imposed new export licensing requirements on exports, re-exports, and in-country transfers of all U.S. - regulated products, software and technology to the designated Huawei entities.

On August 17, 2020, the U.S. Department of Commerce published final regulations expanding the scope of the U.S. EAR to include additional products that became subject to export restrictions relating to Huawei entities including HiSilicon. These new regulations restrict the sale to Huawei and the designated Huawei entities of certain non-U.S. made items, such as semiconductor devices, manufactured for or sold to Huawei entities including HiSilicon under specific, detailed conditions set forth in the new regulations. These new regulations have negatively impacted our sales to Huawei, HiSilicon and their suppliers. Teradyne is taking appropriate actions, including filing for licenses with the U.S. Department of Commerce. However, Teradyne cannot be certain that the actions it takes will mitigate the risks associated with the new export controls that impact its business. It is uncertain the extent these new regulations and any other additional regulations that may be implemented by the U.S. Department of Commerce or other government agency may have on Teradyne's business and financial results.

On April 28, 2020, the U.S. Department of Commerce published new export control regulations for certain U.S. products and technology sold to military end users or for military end-use in China, Russia and Venezuela. The definition of military end user is broad. The regulations went into effect on June 29, 2020. In December 2020, the U.S. Department of Commerce issued a list of companies in China and other countries that it considered to be military end users. Teradyne does not expect that compliance with the new export controls will significantly impact its ability to sell products to its customers in China or to manufacture products in China. The new export controls, however, could disrupt the Company's supply chain, increase compliance costs and impact the demand for the Company's products in China and, thus, have a material adverse impact on Teradyne's business, financial condition or results of operations. In addition, while the Company maintains an export compliance program, its compliance controls could be circumvented, exposing the Company to legal liabilities. Teradyne continues to assess the impact of the new export controls on its business and operations and take appropriate actions, including filing for licenses with the U.S. Department of Commerce, to minimize any disruption. However, Teradyne cannot be certain that the actions it takes will mitigate all the risks associated with the export controls that may impact its business.

In response to the regulations issued by the U.S. Department of Commerce, the Chinese government has passed new laws that may impact Teradyne's business activities in China. The Company continues to assess the potential impact of these new Chinese laws and to monitor relevant laws and regulations issued by the Chinese government.

The global pandemic of the novel strain of the coronavirus (COVID-19) has resulted in authorities implementing numerous measures to try to contain the virus, such as travel bans and restrictions, quarantines, government vaccination mandates and other government regulations. These measures have impacted and may further impact Teradyne's workforce and operations, the operations of its customers, and those of its contract manufacturers and suppliers. As Teradyne implements measures to comply with additional regulations, the Company may experience increased compliance costs, increased risk of non-compliance and increased risk of employee attrition.

The COVID-19 pandemic has adversely impacted the Company's results of operations, including increased costs company-wide and constraints within the Company's supply chain. The Company cannot accurately estimate the amount of the impact on Teradyne's 2021 financial results and to its future financial results. The COVID-19 outbreak has significantly increased economic and demand uncertainty in Teradyne's markets. This uncertainty resulted in a significant decrease in demand for certain Teradyne products and could continue to impact demand for an uncertain period of time. The spread of COVID-19 has caused Teradyne to modify its business practices (including employee travel, employees working remotely, and cancellation of in person participation in meetings, events and conferences) and the Company may take further actions as may be required by government

authorities or that it determines are in the best interests of its employees, customers, contract manufacturers and suppliers. There is uncertainty that such measures will be sufficient to mitigate the risks posed by the virus, and Teradyne's ability to perform critical functions could be impacted. The degree to which COVID-19 continues to impact Teradyne's results will depend on future developments, which are highly uncertain and cannot be predicted, including, but not limited to, the duration and continued spread of the virus, its severity, the actions to contain the virus or the availability and impact of vaccines in countries where the Company does business, and how quickly and to what extent normal economic and operating conditions can resume.

Important factors that could cause actual results, the 2024 earnings model, earnings per share, use of cash, dividend payments, repurchases of common stock, or payment of the senior convertible notes to differ materially from those presently expected include: conditions affecting the markets in which Teradyne operates; decreased or delayed product demand from one or more significant customers; development, delivery and acceptance of new products; the ability to grow the Industrial Automation business; increased research and development spending; deterioration of Teradyne's financial condition; the continued impact of the COVID-19 pandemic and related government responses on the market and demand for Teradyne's products, on its contract manufacturers and supply chain, and on its workforce; the impact of the global semiconductor supply shortage on our supply chain and contract manufacturers; the consummation and success of any mergers or acquisitions; demand for products by the Company's largest customers; unexpected cash needs; insufficient cash flow to make required payments and pay the principal amount on the senior convertible notes; the business judgment of the board of directors that a declaration of a dividend or the repurchase of common stock is not in the company's best interests; additional U.S. tax regulations or IRS guidance; the impact of any tariffs or export controls imposed in the U.S. or China; compliance with trade protection measures or export restrictions; the impact of U.S. Department of Commerce or other government agency regulations relating to Huawei, HiSilicon and other customers or potential customers; and other events, factors and risks disclosed in filings with the SEC, including, but not limited to, the "Risk Factors" sections of Teradyne's Annual Report on Form 10-K for the fiscal year ended December 31, 2020 and Quarterly Report on Form 10-Q for the fiscal quarter ended October 3, 2021. The forward-looking statements provided by Teradyne in this press release represent management's views as of the date of this release. Teradyne anticipates that subsequent events and developments may cause management's views to change. However, while Teradyne may elect to update these forward-looking statements at some point in the future, Teradyne specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Teradyne's views as of any date subsequent to the date of this release.

TERADYNE, INC. REPORT FOR FOURTH FISCAL QUARTER OF 2021

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

	Quarter Ended							Twelve Months Ended				
	De	cember 31, 2021	C	October 3, 2021	De	cember 31, 2020	D	ecember 31, 2021	De	ecember 31, 2020		
Net revenues	\$	885,047	\$	950,501	\$	758,968	\$	3,702,881	\$	3,121,469		
Cost of revenues (exclusive of acquired intangible assets amortization shown separately below) (1)		357,998		379,500		309,179		1,496,225		1,335,728		
Gross profit		527,049		571,001		449,789		2,206,656		1,785,741		
Operating expenses:												
Selling and administrative		142,747		134,829		124,279		547,559		464,769		
Engineering and development		109,965		107,220		100,795		427,609		374,964		
Acquired intangible assets amortization		5,163		5,355		5,752		21,456		30,803		
Restructuring and other (2)		4,738		1,197		(15,117)		1,312	_	(13,202)		
Operating expenses		262,613		248,601		215,709		997,936		857,334		
Income from operations		264,436		322,400		234,080		1,208,720		928,407		
Interest and other expense (3)		1,256		24,645		11,155	_	39,765	_	27,392		
Income before income taxes		263,180		297,755		222,925		1,168,955		901,015		
Income tax provision		32,896		41,037		26,595		148,122		116,868		
Net income	\$	230,284	\$	256,718	\$	196,330	\$	1,020,833	\$	784,147		
Net income per common share:												
Basic	\$	1.41	\$	1.56	\$	1.18	\$	6.19	\$	4.72		
Diluted	\$	1.29	\$	1.41	\$	1.05	\$	5.56	\$	4.28		
Weighted average common shares - basic		162,769		164,583		166,085		164,960		166,120		
Weighted average common shares - diluted (4)		178,020		181,987		186,837		183,625		183,042		

Twelve Months Ended

Twelve Months Ended

(1) Cost of revenues includes:			Twelve Mo	Months Ended						
	Dec	December 31, 2021		October 3, 2021		ember 31, 2020	December 31, 2021		December 31, 2020	
Provision for excess and obsolete inventory	\$	3,700	\$	8,149	\$	4,418	\$	15,475	\$	17,534
Sale of previously written down inventory		(434)		(824)		(593)		(2,477)		(2,315)
Inventory step-up		-				17		<u>-</u>		376
	\$	3,266	\$	7,325	\$	3,842	\$	12,998	\$	15,595

0.10 \$

(2) Restructuring and other consists of:

	December 31, 2021		_	October 3, 2021	De	ecember 31, 2020	De	cember 31, 2021	De	cember 31, 2020
Employee severance	\$	284	\$	617	\$	1,089	\$	1,525	\$	2,309
Acquisition related expenses and compensation		174		275		(902)		488		2,516
Contingent consideration fair value adjustment		-		-		(15,304)		(7,227)		(23,271)
Other		4,280		305				6,526		5,244
	\$	4,738	\$	1,197	\$	(15,117)	\$	1,312	\$	(13,202)

Quarter Ended

Quarter Ended

(3) Interest and other expense includes:

oot and other oxponed monador.										
	Dec	ember 31, 2021	0	ctober 3, 2021	Dec	ember 31, 2020	Dec	ember 31, 2021	December 31, 2020	
Loss on convertible debt conversions	\$	3,431	\$	20,153	\$	-	\$	28,828	\$	-
Non-cash convertible debt interest		1,166		2,262		3,674		10,286		14,426
Pension actuarial (gains) losses		(1,590)		-		7,694		(2,217)		10,284
	\$	3,007	\$	22,415	\$	11,368	\$	36,897	\$	24,710

(4) Under GAAP, when calculating diluted earnings per share, convertible debt must be assumed to have converted if the effect on EPS would be dilutive. Diluted shares assume the conversion of the convertible debt as the effect would be dilutive. Accordingly, for the quarters ended December 31, 2021, October 3, 2021 and December 31, 2020, 3.4 million, 6.5 million and 10.0 million shares, respectively, have been included in diluted shares. For the twelve months ended December 31, 2021 and December 31, 2020, 7.4 million and 8.5 million shares, respectively, have been included in diluted shares. For the quarters ended December 31, 2021, October 3, 2021 and December 31, 2020, diluted shares also included 10.5 million, 9.8 million and 8.9 million shares, respectively, from the convertible note hedge transaction. For the twelve months ended December 31, 2021 and December 31, 2020, diluted shares included 10.0 million and 7.0 million shares, respectively, from the convertible note hedge transaction.

CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands)

	De	ecember 31, 2021	De	ecember 31, 2020
Assets				
Cash and cash equivalents	\$	1,122,199	\$	914,121
Marketable securities		244,231		522,280
Accounts receivable, net		550,749		497,506
Inventories, net		243,330		222,189
Prepayments and other current assets		415,718		259,338
Total current assets		2,576,227		2,415,434
Property, plant and equipment, net		387,240		394,800
Operating lease right-of-use assets, net		68,807		54,569
Marketable securities		133,858		117,980
Deferred tax assets		100,672		87,913
Retirement plans assets		15,110		17,468
Other assets		24,096		9,384
Acquired intangible assets, net		75,635		100,939
Goodwill		426,024		453,859
Total assets	\$	3,807,669	\$	3,652,346

Liabilities				
Accounts payable	\$	153,133	\$	133,663
Accrued employees' compensation and withholdings		253,667		220,321
Deferred revenue and customer advances		146,185		134,662
Other accrued liabilities		116,187		77,581
Operating lease liabilities		19,977		20,573
Income taxes payable		88,789		80,728
Current debt		19,182		33,343
Total current liabilities		797,120		700,871
Retirement plans liabilities		151,141		151,140
Long-term deferred revenue and customer advances		54,921		58,359
Long-term contingent consideration		=		7,227
Long-term other accrued liabilities		15,497		19,352
Deferred tax liabilities		6,327		10,821
Long-term operating lease liabilities		56,178		42,073
Long-term income taxes payable		67,041		74,930
Debt		89,244		376,768
Total liabilities	_	1,237,469	_	1,441,541
Mezzanine equity		1,512		3,787
Shareholders' equity		2,568,688		2,207,018
Total liabilities, convertible common shares and shareholders' equity	\$	3,807,669	\$	3,652,346

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands)

		Quarte	r End	ded		Twelve Mo	nths Ended		
	Dec	cember 31, 2021	De	cember 31, 2020	De	ecember 31, 2021	De	cember 31, 2020	
Cash flows from operating activities:									
Net income	\$	230,284	\$	196,330	\$	1,020,833	\$	784,147	
Adjustments to reconcile net income to net cash provided by operating activities:									
Depreciation		23,207		22,008		91,073		80,119	
Stock-based compensation		10,994		11,878		45,643		44,906	
Amortization		6,786		10,047		34,412		46,624	
Provision for excess and obsolete inventory		3,700		4,418		15,475		17,534	
Loss on convertible debt conversions		3,431		-		28,828		-	
Deferred taxes		(4,802)		(11,141)		(15,534)		(15,688)	
Gains on investments		(1,660)		(4,383)		(6,410)		(7,898)	
Retirement plans actuarial (gains) losses		(1,590)		7,694		(2,217)		10,284	
Contingent consideration fair value adjustment		-		(15,304)		(7,227)		(23,271)	
Other		28		810		271		1,557	
Changes in operating assets and liabilities:									
Accounts receivable		45,521		92,564		(57,778)		(129,451)	
Inventories		(15,448)		(25,436)		6,495		(8,438)	
Prepayments and other assets		(37,282)		(23,667)		(175,846)		(64,418)	
Accounts payable and other liabilities		56,435		(8,390)		121,499		73,167	
Deferred revenue and customer advances		1,174		3,385		9,873		39,974	
Retirement plans contributions		(1,282)		(1,498)		(5,405)		(5,382)	
Income taxes		11,787		1,109		(5,619)		25,169	
Net cash provided by operating activities		331,283		260,424		1,098,366		868,935	

Cook flows from investing patients				
Cash flows from investing activities: Purchases of property, plant and equipment	(29,310)	(38,105)	(132,472)	(184,977)
Purchases of marketable securities	(152,311)	(411,768)	(661,781)	(900,196)
Proceeds from maturities of marketable securities	88,871	170,271	660,148	(900,190 <i>)</i> 479,678
Proceeds from sales of marketable securities	57,029	2,395	266,466	35,006
Purchase of investment	37,029	2,393	•	149
Proceeds from life insurance	-	-	(12,000)	546
	(05.704)	(077,007)	400.004	
Net cash (used for) provided by investing activities	(35,721)	(277,207)	120,361	(569,794)
Cash flows from financing activities:				
Payments of convertible debt principal	(40,993)	-	(342,990)	=
Repurchase of common stock	(193,820)	=	(600,000)	(88,465)
Dividend payments	(16,266)	(16,612)	(65,977)	(66,482)
Payments related to net settlement of employee stock compensation awards	(258)	(279)	(32,303)	(23,014)
Issuance of common stock under stock purchase and stock option plans	96	1,999	32,686	28,527
Payments of contingent consideration	-	=	-	(8,852)
Net cash used for financing activities	(251,241)	(14,892)	(1,008,584)	(158,286)
Effects of exchange rate changes on cash and cash equivalents	(1,576)	616	(2,065)	(658)
Increase (decrease) in cash and cash equivalents	42,745	(31,059)	208,078	140,197
Cash and cash equivalents at beginning of period	1,079,454	945,180	914,121	773,924
Cash and cash equivalents at end of period	\$ 1,122,199	\$ 914,121	\$ 1,122,199	\$ 914,121

GAAP to Non-GAAP Earnings Reconciliation

(In millions, except per share amounts)

					Quarte	r Ended		
		ecember 1, 2021	% of Net Revenues			% of Net Revenues	ecember 1, 2020	% of Net Revenues
Net revenues	\$	885.0		\$	950.5		\$ 759.0	
Gross profit GAAP	\$	527.0	59.5%	\$	571.0	60.1%	\$ 449.8	59.3%
Gross profit non-GAAP	\$	527.0	59.5%	\$	571.0	60.1%	\$ 449.8	59.3%
Income from operations - GAAP	\$	264.4	29.9%	\$	322.4	33.9%	\$ 234.1	30.8%
Restructuring and other (1)		4.7	0.5%		1.2	0.1%	(15.1)	-2.0%
Acquired intangible assets amortization	5	5.2	0.6%		5.4	0.6%	5.8	0.8%
Equity modification charge		-			-	-	 0.8	0.1%
Income from operations - non-GAAP	\$	274.3	31.0%	\$	329.0	34.6%	\$ 225.6	29.7%

	5				ome per on Share				Net Income per Common Share				
		cember 1, 2021	% of Net Revenues	Basic	Diluted	ctober 3, 2021	% of Net Revenues	Basic	Diluted	cember I, 2020	% of Net Revenues	Basic	Diluted
Net income - GAAP	\$	230.3	26.0%	\$ 1.41	\$ 1.29	\$ 256.7	27.0%	\$ 1.56	\$ 1.41	\$ 196.3	25.9%	\$ 1.18	\$ 1.05
Restructuring and other (1)		4.7	0.5%	0.03	0.03	1.2	0.1%	0.01	0.01	(15.1)	-2.0%	(0.09)	(0.08)

Acquired intangible assets amortization	5.2	0.6%	0.03	0.03	5.4	0.6%	0.03	0.03	5.8	0.8%	0.03	0.03
Loss on convertible debt conversions (2)	3.4	0.4%	0.02	0.02	20.2	2.1%	0.12	0.11	-	-	-	-
Interest and other (2)	1.2	0.1%	0.01	0.01	2.3	0.2%	0.01	0.01	3.7	0.5%	0.02	0.02
Pension mark-to- market adjustment (2)	(1.6)	-0.2%	(0.01)	(0.01)	-	-	-	-	7.7	1.0%	0.05	0.04
Equity modification charge	-	-	-	-	-	-	-	-	0.8	0.1%	0.00	0.00
Exclude discrete tax adjustments	(6.5)	-0.7%	(0.04)	(0.04)	(5.9)	-0.6%	(0.04)	(0.03)	(2.1)	-0.3%	(0.01)	(0.01)
Non-GAAP tax adjustments	1.7	0.2%	0.01	0.01	(1.3)	-0.1%	(0.01)	(0.01)	(3.9)	-0.5%	(0.02)	(0.02)
Convertible share adjustment (3)	-	-	-	0.03	-	-	-	0.06	-	-	-	0.06
Net income - non-GAAP	\$ 238.4	26.9%	\$ 1.46	\$ 1.37	\$ 278.6	29.3%	\$ 1.69	\$ 1.59	\$ 193.2	25.5%	\$ 1.16	\$ 1.10
GAAP and non-GAAP weighted average common shares - basic	162.8				164.6				166.1			
GAAP weighted average common shares - diluted	178.0				182.0				186.8			
Exclude												
dilutive shares related to convertible note transaction	(3.4)				(6.5)				(10.0)			

(1) Restructuring and other consists of:

			Quarte	r Ended		
	December 31, 2021			ctober 2021	December 31, 2020	
Employee severance Acquisition	\$	0.3	\$	0.6	\$ 1.1	
related expenses and compensation Contingent		0.2		0.3	(0.9)	
consideration fair value adjustment		-		-	(15.3)	
Other		4.3		0.3	 _	
	\$	4.7	\$	1.2	\$ (15.1)	

⁽²⁾ For the quarters ended December 31, 2021, October 3, 2021, and December 31, 2020, Interest and other includes non-cash convertible debt interest expense. For the quarters ended December 31, 2021 and October 3, 2021, adjustment to exclude loss on convertible debt conversions. For the quarters ended December 31, 2021 and December 31, 2020, adjustments to exclude actuarial (gain) loss recognized under GAAP in accordance with Teradyne's mark-to-market pension accounting.

(3) For the quarters ended December 31, 2021, October 3, 2021, and December 31, 2020, the non-GAAP diluted EPS calculation adds back \$0.4 million, \$0.5 million, and \$1.7 million, respectively, of convertible debt interest expense to non-GAAP net income, and non-GAAP weighted average diluted common shares include 10.5 million, 9.8 million and 8.9 million shares, respectively, from the convertible note hedge transaction.

Net Income per

	Twelve Months Ended				
	December 31, 2021	% of Net Revenues	December 31, 2020	% of Net Revenues	
Net Revenues	\$ 3,702.9		\$ 3,121.5		
Gross profit GAAP	\$ 2,206.7	59.6%	\$ 1,785.7	57.2%	
Inventory step-up			0.4	0.0%	
Gross profit non-GAAP	\$ 2,206.7	59.6%	\$ 1,786.1	57.2%	
Income from operations - GAAP Acquired	\$ 1,208.7	32.6%	\$ 928.4	29.7%	
intangible assets amortization	21.5	0.6%	30.8	1.0%	
Restructuring and other (1)	1.3	0.0%	(13.2)	-0.4%	
Inventory step-up	-	-	0.4	0.0%	
Equity modification charge	-	-	0.8	0.0%	
Income from operations - non-GAAP	\$ 1,231.5	33.3%	\$ 947.2	30.3%	

				ome per on Share			Con	ome per imon are
	December 31, 2021	% of Net Revenues	Basic	Diluted	December 31, 2020	% of Net Revenues	Basic	Diluted
Net income - GAAP	\$ 1,020.8	27.6%	\$ 6.19	\$ 5.56	\$ 784.1	25.1%	\$ 4.72	\$ 4.28
Acquired intangible assets amortization	21.5	0.6%	0.13	0.12	30.8	1.0%	0.19	0.17
Restructuring and other (1)	1.3	0.0%	0.01	0.01	(13.2)	-0.4%	(80.0)	(0.07)
Interest and other (2)	10.3	0.3%	0.06	0.06	14.4	0.5%	0.09	0.08
Loss on convertible debt conversions (2)	28.8	0.8%	0.17	0.16	-	-	-	-
Pension mark-to- market adjustment (2)	(2.2)	-0.1%	(0.01)	(0.01)	10.3	0.3%	0.06	0.06
Inventory step-up	-	-	-	-	0.4	0.0%	0.00	0.00
Equity modification charge	-	-	-	-	0.8	0.0%	0.00	0.00
Exclude discrete tax adjustments	(28.6)	-0.8%	(0.17)	(0.16)	(15.2)	-0.5%	(0.09)	(0.08)
Non-GAAP tax adjustments	(1.5)	-0.0%	(0.01)	(0.01)	(11.9)	-0.4%	(0.07)	(0.07)
Convertible share adjustment (3)	-			0.24		-	_	0.25
Net income - non-GAAP	\$ 1,050.4	28.4%	\$ 6.37	\$ 5.98	\$ 800.5	25.6%	\$ 4.82	\$ 4.62

GAAP and non-GAAP weighted average common shares - basic	165.0		166.1
GAAP weighted			
average common	183.6		183.0
shares - diluted			
Exclude dilutive shares from convertible note	(7.4)	_	(8.5)
Non-GAAP weighted average common shares - diluted	176.2		174.5

(1) Restructuring and other consists of:

	Twelve Months Ended			
	December 31, 2021			cember I, 2020
Employee severance	\$	1.5		\$ 2.3
Acquisition related expenses and compensation		0.5		2.5
Contingent consideration fair value adjustment		(7.2)		(23.3)
Other		6.5		 5.2
	\$	1.3		\$ (13.2)

- (2) For the twelve months ended December 31, 2021 and December 31, 2020, Interest and other included non-cash convertible debt interest expense. For the twelve months ended December 31, 2021, adjustment to exclude loss on convertible debt conversions. For the twelve months ended December 31, 2021 and December 31, 2020, adjustments to exclude actuarial (gain) loss recognized under GAAP in accordance with Teradyne's mark-to-market pension accounting.
- (3) For the twelve months ended December 31, 2021 and December 31, 2020, the non-GAAP diluted EPS calculation adds back \$3.7 million and \$6.8 million, respectively, of convertible debt interest expense to non-GAAP net income and non-GAAP weighted average diluted common shares include 10.0 million and 7.0 million shares, respectively, related to the convertible debt hedge transaction.

GAAP to Non-GAAP Reconciliation of First Quarter 2022 guidance:

GAAP and			
non-GAAP first		\$700	to \$770
quarter revenue	r	nillion	million
guidance:			
GAAP net income	Φ	0.74	ф o oo
per diluted share	\$	0.71	\$ 0.93
Exclude acquired			
intangible assets		0.03	0.03
amortization			
Exclude			
non-cash		0.01	0.04
convertible debt		0.01	
interest			
Tax effect of			
non-GAAP		(0.01)	(0.01)
adjustments			
Convertible		0.01	0.00
share adjustment		0.01	0.02
Non-GAAP net		•	
income per diluted	\$	0.76	\$ 0.98
share			

	Twelve Months Ended			
			C	Net (Loss) ncome per ommon Share
		cember 1, 2016		Diluted
Net loss - GAAP	\$	(43.4)	\$	(0.21)
Goodwill impairment (1) Acquired		254.9		1.25
intangible assets impairment (1) Acquired		83.3		0.41
intangible assets amortization		52.6		0.26
Restructuring and other (2)		21.9		0.11
Pension mark-to- market adjustments (3)		(3.2)		(0.02)
Interest and other (4)		0.6		0.00
Exclude discrete tax adjustments (5)		(4.5)		(0.02)
Tax effect of non-GAAP adjustments		(53.3)		(0.26)
Net income - non-GAAP	\$	308.9	\$	1.51
GAAP and non-GAAP weighted average common shares - basic		202.6		
GAAP weighted average common shares - diluted		202.6		
Include dilutive shares		1.8		
Non-GAAP weighted average common shares - diluted		204.4		

- (1) Goodwill and acquired intangible assets impairment related to Teradyne's Wireless Test business segment.
- (2) Restructuring and other consists of:

	Twelve Months Ended		
	December 31, 2016		
Contingent consideration fair value adjustment	\$	15.9	
Employee severance		6.0	

Impairment of	
fixed assets	
and expenses	5.4
related to	5.4
Japan	
earthquake	
Property	
insurance	(5.4)
recovery	
	\$ 21.9

- (3) Actuarial (gains) losses recognized under GAAP in accordance with Teradyne's mark-to-market pension accounting.
- (4) For the year ended December 31, 2016, Interest and other included non-cash convertible debt interest expense.
- (5) For the year ended December 31, 2016, adjustment to exclude discrete income tax items and an adjustment to treat Wireless Test business segment goodwill and intangible assets impairments as discrete tax items.

GAAP to Non-GAAP Reconciliation of 2024 Earnings Model:

	Mid Point of 2024 Earnings Model				
		Net Income per Common Share			
	December 31, 2024		Diluted		
Net Income - GAAP	\$ 1,321.3	\$	7.90		
Acquired intangible assets amortization	19.5		0.12		
Tax effect of non-GAAP adjustment	(3.3)		(0.02)		
Net income - non-GAAP	\$ 1,337.5	\$	8.00		

For press releases and other information of interest to investors, please visit Teradyne's homepage at http://www.teradyne.com.

Contact:

Teradyne, Inc.

Andy Blanchard 978-370-2425

Vice President of Corporate Relations

TERADYNE

Source: Teradyne, Inc.